Serono, Syntonix to collaborate on long-acting infertility treatment

By E. Janene Geiss

Philadelphia, Sept. 18 - Serono SA and Syntonix Pharmaceuticals Inc. said Monday that they have agreed to jointly evaluate Syntonix' FSH:Fc SynFusion products for further development.

Syntonix's SynFusion and Transceptor technologies may enable the development of a long-acting FSH therapy for the treatment of infertility that can be inhaled and dosed less frequently, instead of injected daily, according to joint news release.

Under the agreement, Syntonix said it has provided Serono with an exclusive option to license exclusive, worldwide rights for the development and commercialization of Syntonix' FSH:Fc SynFusion drugs.

Serono said it will decide whether to exercise the option after further evaluation of the FSH:Fc candidates. Serono will pay Syntonix, the Waltham, Mass.-based biopharmaceutical company, a collaboration and option fee.

If Geneva, Switzerland-based Serono exercises the option, Syntonix will receive an additional upfront license fee and will be eligible for milestone fees worth up to $54 million as well as royalties upon commercialization. Additional financial terms were not disclosed.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.